20Jul/13

Astellas Announces FDA Approval of ASTAGRAF XL™ (tacrolimus extended … – PR Newswire (press release)

Astellas Announces FDA Approval of ASTAGRAF XL™ (tacrolimus extended
PR Newswire (press release)
The two primary, randomized, comparative phase 3 clinical studies to support FDA approval enrolled 1,093 patients (545 on tacrolimus extended-release) in the U.S., Europe, Canada, South America, Australia and South Africa. Astellas was granted

20Jul/13

FDA approves Astellas' ASTAGRAF XL for prophylaxis of organ rejection in … – News-Medical.net

FDA approves Astellas’ ASTAGRAF XL for prophylaxis of organ rejection in
News-Medical.net
Administration (FDA) has approved ASTAGRAF XLTM (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil (MMF) and corticosteroids, with or without